Want to see HK:6618 full AI Analyst Report?
Top Page
JD Health International, Inc.
(6618)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$39.00
▲(6.15% Upside)
Action:Reiterated
Date:08/19/26
The score is driven primarily by strong financial performance—especially the very low leverage and improving profitability—supported by a constructive earnings call highlighting margin expansion, solid operating cash generation, and a strong liquidity position. Offsetting factors are the 2025 free-cash-flow drop to zero and a mixed technical picture (still below longer-term moving averages), while valuation (P/E ~17.5) looks reasonable but not clearly discounted.
Positive Factors
Revenue Growth
Strong product and service revenue growth indicates continued customer demand and expanding commercial scale. Sustained top-line momentum can improve operating leverage, support investment in healthcare capabilities, and reinforce JD Health’s competitive position over the next several quarters.
Negative Factors
Free Cash Flow Reset
The sharp free-cash-flow reset weakens near-term internal funding capacity even though operating cash generation remains strong. If investment or working-capital needs stay elevated, cash conversion could constrain flexibility for expansion, buybacks, or other capital allocation priorities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong product and service revenue growth indicates continued customer demand and expanding commercial scale. Sustained top-line momentum can improve operating leverage, support investment in healthcare capabilities, and reinforce JD Health’s competitive position over the next several quarters.
Read all positive factors
JD Health International, Inc. (6618) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$112.50B
Dividend YieldN/A
Average Volume (3M)9.27M
Price to Earnings (P/E)15.4
Beta (1Y)1.38
Revenue Growth25.80%
EPS Growth35.81%
CountryHK
Employees6,018
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)1.92
Shares Outstanding3,190,481,000
10 Day Avg. Volume6,994,830
30 Day Avg. Volume9,270,226
Financial Highlights & Ratios
PEG Ratio1.09
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio16.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$65.33Price Target Upside77.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.87
Revenue Forecast (FY)HK$85.70B
JD Health International, Inc. Business Overview & Revenue Model
Company Description
JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as o...
JD Health International, Inc. Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 29, 2027
Earnings Call Sentiment Positive
The call presented a largely positive operating and financial picture: strong H1 revenue (RMB 40.9 billion) and product revenue growth (15.6%), substantial improvement in non-IFRS operating income (+40.3%) and margin expansion to 8.5%, robust cash generation (RMB 4.46 billion) and a solid liquidity position (RMB 71.5 billion). Operational progress included AI traction (Dr. Da Wei user base 4x), platform and offline expansion (450+ pharmacies, 65 new drugs), and disciplined expense management (marketing ratio down 0.5 pts). Offsetting these strengths were short-term headwinds in nutrition & supplements from regulatory action and counterfeit-brand issues, a slowdown in some non-pharmaceutical growth, early-stage AI monetization, fulfillment cost pressures, and an expected deceleration in H2 growth. Overall, the positives—strong top-line, meaningful profitability gains, healthy cash and tangible AI & offline execution—outweigh the manageable risks and short-term challenges.Positive Updates
Strong Revenue and Product Growth
Total revenue reached RMB 40.9 billion in H1 2026. Product revenue grew 15.6% year-over-year to RMB 33.9 billion, while service revenue was RMB 7.0 billion, indicating diversified top-line drivers.
Negative Updates
Slower Growth in Non-Pharmaceutical Categories
Non-pharmaceutical product revenue growth slowed slightly in H1, with management noting nutrition & supplements performed below expectations in the short term and requiring further execution to regain momentum.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue and Product Growth
Total revenue reached RMB 40.9 billion in H1 2026. Product revenue grew 15.6% year-over-year to RMB 33.9 billion, while service revenue was RMB 7.0 billion, indicating diversified top-line drivers.
Read all positive updates
Company Guidance
Management guided that JD Health expects to maintain H2 growth better than the industry and to drive sustained profitability—targeting a high single‑digit operating margin long term—while continuing disciplined AI investment and its USD 1.0 billion, four‑year share repurchase program (RMB 840 million repurchased/canceled in the quarter, ~USD 110 million / HKD 840 million). Management pointed to H1 operating momentum to support this outlook: total revenue RMB 40.9 billion, product revenue RMB 33.9 billion (+15.6% YoY), service revenue RMB 7.0 billion, non‑IFRS operating income RMB 3.5 billion (+40.3% YoY) with a non‑IFRS operating margin of 8.5% (up 1.5 ppt), gross profit RMB 10.6 billion (gross margin 26.1%, +0.9 ppt), non‑IFRS net income ~RMB 3.9 billion, net cash from operations RMB 4.46 billion and cash/restricted cash/term deposits/wealth products RMB 71.5 billion (+RMB 2.0 billion YoY); other operating metrics included 65 new drugs launched, JD Pharmacy >450 stores in 10 cities, medical‑insurance payment in 40 cities (added 11), advertising merchants +20% YoY, fulfillment expense ratio 10% (flat), marketing expense ratio 4.6% (‑0.5 ppt), R&D ratio 2.3% (+0.2 ppt), AI user base for Dr. Da Wei up 4x, and finance income ~RMB 840 million.JD Health International, Inc. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 78.47B | 73.44B | 58.16B | 53.53B | 46.74B | 30.68B |
| Gross Profit | 19.85B | 18.20B | 13.31B | 11.87B | 9.89B | 7.20B |
| EBITDA | 5.02B | 3.98B | 1.31B | 2.93B | -60.93M | -1.37B |
| Net Income | 6.17B | 5.38B | 4.16B | 2.14B | 380.11M | -1.07B |
Balance Sheet | ||||||
| Total Assets | 84.16B | 81.62B | 71.27B | 64.29B | 61.28B | 48.00B |
| Cash, Cash Equivalents and Short-Term Investments | 47.41B | 48.15B | 51.24B | 41.22B | 47.67B | 41.99B |
| Total Debt | 874.69M | 636.29M | 258.39M | 214.75M | 199.41M | 201.27M |
| Total Liabilities | 22.71B | 21.52B | 16.03B | 14.92B | 16.49B | 8.15B |
| Stockholders Equity | 61.44B | 60.10B | 55.23B | 49.36B | 44.78B | 39.85B |
Cash Flow | ||||||
| Free Cash Flow | 8.31B | 9.75B | 4.29B | 4.54B | 5.86B | 2.93B |
| Operating Cash Flow | 8.53B | 9.94B | 4.33B | 4.60B | 5.91B | 3.43B |
| Investing Cash Flow | -11.61B | -599.64M | 3.15B | -8.02B | -4.24B | -17.75B |
| Financing Cash Flow | -963.36M | -77.10M | -45.61M | -117.20M | -925.45M | -163.65M |
JD Health International, Inc. Technical Analysis
Negative
36.74
Price Trends
37.84
Negative
39.27
Negative
48.37
Negative
Market Momentum
-0.73
Positive
34.19
Neutral
26.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6618, the sentiment is Negative. The current price of 36.74 is below the 20-day moving average (MA) of 37.25, below the 50-day MA of 37.84, and below the 200-day MA of 48.37, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 34.19 is Neutral, neither overbought nor oversold. The STOCH value of 26.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6618.
JD Health International, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$112.50B | 15.44 | 10.15% | ― | 25.80% | 35.81% | |
67 Neutral | HK$1.02B | 9.74 | 5.57% | 2.41% | 4.75% | ― | |
62 Neutral | HK$6.32B | 29.69 | 2.50% | 0.39% | 1.59% | -58.55% | |
56 Neutral | HK$1.23B | 84.76 | 0.48% | 1.02% | -3.26% | ― | |
55 Neutral | HK$5.96B | 25.62 | 1.87% | 1.94% | 6.52% | ― | |
52 Neutral | HK$984.05M | -19.78 | -1.56% | 10.05% | 7.95% | 60.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6618
JD Health International, Inc.
34.64
-34.71
-50.05%
HK:9960
Kindstar Globalgene Technology, Inc.
0.95
-0.43
-31.17%
HK:1951
Jinxin Fertility Group Ltd.
2.16
-0.53
-19.62%
HK:3309
C-MER Eye Care Holdings Limited
0.82
-1.08
-56.84%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-31.13%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
10.06
-4.12
-29.06%
JD Health International, Inc. Corporate Events
JD Health Boosts Profitability on Policy-Backed Healthcare and AI Expansion
Aug 13, 2026
JD Health reported interim results for the first half of 2026, with revenue rising 15.9% year-on-year to RMB40.9 billion and gross profit up 20.2%. Operating income surged 49.2% to RMB3.17 billion, while non-IFRS operating income climbed 40.3% and...
JD Health Sets August 13 Board Meeting to Approve Interim Results
Jul 31, 2026
JD Health International Inc. has scheduled a board meeting for August 13, 2026 to approve and publish its unaudited interim results for the six months ended June 30, 2026, and to consider whether to recommend an interim dividend. The timing signal...
JD Health Shareholders Approve All Resolutions at 2026 AGM
Jun 29, 2026
JD Health International Inc., a Cayman Islands–incorporated healthcare and health-tech company listed on the Hong Kong Stock Exchange, focuses on providing online medical services, pharmaceutical retail and broader digital health solutions w...
JD Health Restructures VIE Shareholding While Keeping HKEX Waiver Intact
Jun 26, 2026
JD Health International has restructured the ownership of its consolidated variable interest entity Suqian Tianning, transferring a 45% equity stake from existing shareholder Qin Miao to JD Group vice president Saili Tan, while keeping the remaini...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.